<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR314.html">Part 314
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 314.53  Submission of patent information.
                            </h3>
                            <p class="depth0"><em>(a)</em> Who must submit patent information. This section applies to any  applicant who submits to FDA a new drug application or an amendment to  it under section 505(b) of the act and Sec. 314.50 or a supplement to  an approved application under Sec. 314.70, except as provided in  paragraph (d)(2) of this section.</p><p class="depth0"><em>(b)</em> Patents for which information must be submitted and patents for  which information must not be submitted--</p><p class="depth0"><em>(1)</em> General requirements. An  applicant described in paragraph (a) of this section shall submit the  required information on the declaration form set forth in paragraph (c)  of this section for each patent that claims the drug or a method of  using the drug that is the subject of the new drug application or  amendment or supplement to it and with respect to which a claim of  patent infringement could reasonably be asserted if a person not  licensed by the owner of the patent engaged in the manufacture, use, or  sale of the drug product. For purposes of this part, such patents  consist of drug substance (active ingredient) patents, drug product  (formulation and composition) patents, and method-of-use patents. For  patents that claim the drug substance, the applicant shall submit  information only on those patents that claim the drug substance that is  the subject of the pending or approved application or that claim a drug  substance that is the same as the active ingredient that is the subject  of the approved or pending application. For patents that claim a  polymorph that is the same as the active ingredient described in the  approved or pending application, the applicant shall certify in the  declaration forms that the applicant has test data, as set forth in  paragraph (b)(2) of this section, demonstrating that a drug product  containing the polymorph will perform the same as the drug product  described in the new drug application. For patents that claim a drug  product, the applicant shall submit information only on those patents  that claim a drug product, as is defined in Sec. 314.3, that is  described in the pending or approved application. For patents that claim  a method of use, the applicant shall submit information only on those  patents that claim indications or other conditions of use that are  described in the pending or approved application. The applicant shall  separately identify each pending or approved method of use and related  patent claim. For approved applications, the applicant submitting the  method-of-use patent shall identify with specificity the section of the  approved labeling that corresponds to the method of use claimed by the  patent submitted. Process patents, patents claiming packaging, patents  claiming metabolites, and patents claiming intermediates are not covered  by this section, and information on these patents must not be submitted  to FDA.</p><p class="depth0"><em>(2)</em> Test Data for Submission of Patent Information for Patents That  Claim a Polymorph. The test data, referenced in paragraph (b)(1) of this  section, must include the following:</p><p class="depth0"><em>(i)</em> A full description of the polymorphic form of the drug  substance, including its physical and chemical characteristics and  stability; the method of synthesis (or isolation) and purification of  the drug substance; the process controls used during manufacture and  packaging; and such specifications and analytical methods as are  necessary to assure the identity, strength, quality, and purity of the  polymorphic form of the drug substance;</p><p class="depth0"><em>(ii)</em> The executed batch record for a drug product containing the  polymorphic form of the drug substance and documentation that the batch  was manufactured under current good manufacturing practice requirements;</p><p class="depth0"><em>(iii)</em> Demonstration of bioequivalence between the executed batch of  the drug product that contains the polymorphic form of the drug  substance and the drug product as described in the NDA;</p><p class="depth0"><em>(iv)</em> A list of all components used in the manufacture of the drug  product containing the polymorphic form and a statement of the  composition of the drug product; a statement of the specifications and  analytical methods for each component; a description of the  manufacturing and packaging procedures and in-process controls for the  drug product; such specifications and analytical methods as are  necessary to assure the identity, strength, quality, purity, and  bioavailability of the drug product, including release and stability  data complying with the approved product specifications to demonstrate  pharmaceutical equivalence and comparable product stability; and</p><p class="depth0"><em>(v)</em> Comparative in vitro dissolution testing on 12 dosage units each  of the executed test batch and the new drug application product.</p><p class="depth0"><em>(c)</em> Reporting requirements--</p><p class="depth0"><em>(1)</em> General requirements. An applicant  described in paragraph (a) of this section shall submit the required  patent information described in paragraph (c)(2) of this section for  each patent that meets the requirements described in paragraph (b) of  this section. We will not accept the patent information unless it is  complete and submitted on the appropriate forms, FDA Forms 3542 or  3542a. These forms may be obtained on the Internet at http://www.fda.gov  by searching for ``forms''.</p><p class="depth0"><em>(2)</em> Drug substance (active ingredient), drug product (formulation or  composition), and method-of-use patents--</p><p class="depth0"><em>(i)</em> Original Declaration. For  each patent that claims a drug substance (active ingredient), drug  product (formulation and composition), or method of use, the applicant  shall submit FDA Form 3542a. The following information and verification  is required:</p><p class="depth0"><em>(A)</em> New drug application number;</p><p class="depth0"><em>(B)</em> Name of new drug application sponsor;</p><p class="depth0"><em>(C)</em> Trade name (or proposed trade name) of new drug;</p><p class="depth0"><em>(D)</em> Active ingredient(s) of new drug;</p><p class="depth0"><em>(E)</em> Strength(s) of new drug;</p><p class="depth0"><em>(F)</em> Dosage form of new drug;</p><p class="depth0"><em>(G)</em> United States patent number, issue date, and expiration date of  patent submitted;</p><p class="depth0"><em>(H)</em> The patent owner's name, full address, phone number and, if  available, fax number and e-mail address;</p><p class="depth0"><em>(I)</em> The name, full address, phone number and, if available, fax  number and e-mail address of an agent or representative who resides or  maintains a place of business within the United States authorized to  receive notice of patent certification under sections 505(b)(3) and  505(j)(2)(B) of the act and Sec. Sec. 314.52 and 314.95 (if patent  owner or new drug application applicant or holder does not reside or  have a place of business within the United States);</p><p class="depth0"><em>(J)</em> Information on whether the patent has been submitted previously  for the new drug application;</p><p class="depth0"><em>(K)</em> Information on whether the expiration date is a new expiration  date if the patent had been submitted previously for listing;</p><p class="depth0"><em>(L)</em> Information on whether the patent is a product-by-process patent  in which the product claimed is novel;</p><p class="depth0"><em>(M)</em> Information on the drug substance (active ingredient) patent  including the following:</p><p class="depth0"><em>(1)</em> Whether the patent claims the drug substance that is the active  ingredient in the drug product described in the new drug application or  supplement;</p><p class="depth0"><em>(2)</em> Whether the patent claims a polymorph that is the same active  ingredient that is described in the pending application or supplement;</p><p class="depth0"><em>(3)</em> Whether the applicant has test data, described in paragraph  (b)(2) of this section, demonstrating that a drug product containing the  polymorph will perform the same as the drug product described in the new  drug application or supplement, and a description of the polymorphic  form(s) claimed by the patent for which such test data exist;</p><p class="depth0"><em>(4)</em> Whether the patent claims only a metabolite of the active  ingredient; and</p><p class="depth0"><em>(5)</em> Whether the patent claims only an intermediate;</p><p class="depth0"><em>(N)</em> Information on the drug product (composition/formulation) patent  including the following:</p><p class="depth0"><em>(1)</em> Whether the patent claims the drug product for which approval is  being sought, as defined in Sec. 314.3; and</p><p class="depth0"><em>(2)</em> Whether the patent claims only an intermediate;</p><p class="depth0"><em>(O)</em> Information on each method-of-use patent including the  following:</p><p class="depth0"><em>(1)</em> Whether the patent claims one or more methods of using the drug  product for which use approval is being sought and a description of each  pending method of use or related indication and related patent claim of  the patent being submitted; and</p><p class="depth0"><em>(2)</em> Identification of the specific section of the proposed labeling  for the drug product that corresponds to the method of use claimed by  the patent submitted;</p><p class="depth0"><em>(P)</em> Whether there are no relevant patents that claim the drug  substance (active ingredient), drug product (formulation or composition)  or method(s) of use, for which the applicant is seeking approval and  with respect to which a claim of patent infringement could reasonably be  asserted if a person not licensed by the owner of the patent engaged in  the manufacture, use, or sale of the drug product;</p><p class="depth0"><em>(Q)</em> A signed verification which states:</p><p class="depth0">``The undersigned declares that this is an accurate and complete  submission of patent information for the NDA, amendment or supplement  pending under section 505 of the Federal Food, Drug, and Cosmetic Act.  This time-sensitive patent information is submitted pursuant to 21 CFR  314.53. I attest that I am familiar with 21 CFR 314.53 and this  submission complies with the requirements of the regulation. I verify  under penalty of perjury that the foregoing is true and correct.''; and</p><p class="depth0"><em>(R)</em> Information on whether the applicant, patent owner or attorney,  agent, representative or other authorized official signed the form; the  name of the person; and the full address, phone number and, if  available, the fax number and e-mail address.</p><p class="depth0"><em>(ii)</em> of this  section. As described in paragraph (d)(4) of this section, patent  information must be submitted to FDA within 30 days of the date of  issuance of the patent. If the applicant submits the required patent  information within the 30 days, but we notify an applicant that a  declaration form is incomplete or shows that the patent is not eligible  for listing, the applicant must submit an acceptable declaration form  within 15 days of FDA notification to be considered timely filed. The  following information and verification statement is required:</p><p class="depth0"><em>(A)</em> New drug application number;</p><p class="depth0"><em>(B)</em> Name of new drug application sponsor;</p><p class="depth0"><em>(C)</em> Trade name of new drug;</p><p class="depth0"><em>(D)</em> Active ingredient(s) of new drug;</p><p class="depth0"><em>(E)</em> Strength(s) of new drug;</p><p class="depth0"><em>(F)</em> Dosage form of new drug;</p><p class="depth0"><em>(G)</em> Approval date of new drug application or supplement;</p><p class="depth0"><em>(H)</em> United States patent number, issue date, and expiration date of  patent submitted;</p><p class="depth0"><em>(I)</em> The patent owner's name, full address, phone number and, if  available, fax number and e-mail address;</p><p class="depth0"><em>(J)</em> The name, full address, phone number and, if available, fax  number   and e-mail address of an agent or representative who resides or  maintains a place of business within the United States authorized to  receive notice of patent certification under sections 505(b)(3) and  505(j)(2)(B) of the act and Sec. Sec. 314.52 and 314.95 (if patent  owner or new drug application applicant or holder does not reside or  have a place of business within the United States);</p><p class="depth0"><em>(K)</em> Information on whether the patent has been submitted previously  for the new drug application;</p><p class="depth0"><em>(L)</em> Information on whether the expiration date is a new expiration  date if the patent had been submitted previously for listing;</p><p class="depth0"><em>(M)</em> Information on whether the patent is a product-by-process patent  in which the product claimed is novel;</p><p class="depth0"><em>(N)</em> Information on the drug substance (active ingredient) patent  including the following:</p><p class="depth0"><em>(1)</em> Whether the patent claims the drug substance that is the active  ingredient in the drug product described in the approved application;</p><p class="depth0"><em>(2)</em> Whether the patent claims a polymorph that is the same as the  active ingredient that is described in the approved application;</p><p class="depth0"><em>(3)</em> Whether the applicant has test data, described at paragraph  (b)(2) of this section, demonstrating that a drug product containing the  polymorph will perform the same as the drug product described in the  approved application and a description of the polymorphic form(s)  claimed by the patent for which such test data exist;</p><p class="depth0"><em>(4)</em> Whether the patent claims only a metabolite of the active  ingredient; and</p><p class="depth0"><em>(5)</em> Whether the patent claims only an intermediate;</p><p class="depth0"><em>(O)</em> Information on the drug product (composition/formulation) patent  including the following:</p><p class="depth0"><em>(1)</em> Whether the patent claims the approved drug product as defined  in Sec. 314.3; and</p><p class="depth0"><em>(2)</em> Whether the patent claims only an intermediate;</p><p class="depth0"><em>(P)</em> Information on each method-of-use patent including the  following:</p><p class="depth0"><em>(1)</em> Whether the patent claims one or more approved methods of using  the approved drug product and a description of each approved method of  use or indication and related patent claim of the patent being  submitted;</p><p class="depth0"><em>(2)</em> Identification of the specific section of the approved labeling  for the drug product that corresponds to the method of use claimed by  the patent submitted; and</p><p class="depth0"><em>(3)</em> The description of the patented method of use as required for  publication;</p><p class="depth0"><em>(Q)</em> Whether there are no relevant patents that claim the approved  drug substance (active ingredient), the approved drug product  (formulation or composition) or approved method(s) of use and with  respect to which a claim of patent infringement could reasonably be  asserted if a person not licensed by the owner of the patent engaged in  the manufacture, use, or sale of the drug product;</p><p class="depth0"><em>(R)</em> A signed verification which states: ``The undersigned declares  that this is an accurate and complete submission of patent information  for the NDA, amendment or supplement approved under section 505 of the  Federal Food, Drug, and Cosmetic Act. This time-sensitive patent  information is submitted pursuant to 21 CFR 314.53. I attest that I am  familiar with 21 CFR 314.53 and this submission complies with the  requirements of the regulation. I verify under penalty of perjury that  the foregoing is true and correct.''; and</p><p class="depth0"><em>(S)</em> Information on whether the applicant, patent owner or attorney,  agent, representative or other authorized official signed the form; the  name of the person; and the full address, phone number and, if  available, the fax number and e-mail address.</p><p class="depth0"><em>(3)</em> No relevant patents. If the applicant believes that there are no  relevant patents that claim the drug substance (active ingredient), drug  product (formulation or composition), or the method(s) of use for which  the applicant has received approval, and with respect to which a claim  of patent infringement could reasonably be asserted if a person not  licensed by the owner of the patent engaged in the manufacture, use, or  sale of the drug product, the applicant will verify this information in  the appropriate forms, FDA Forms 3542 or 3542a.</p><p class="depth0"><em>(4)</em> Authorized signature. The declarations required by this section  shall be signed by the applicant or patent owner, or the applicant's or  patent owner's attorney, agent (representative), or other authorized  official.</p><p class="depth0"><em>(d)</em> When and where to submit patent information--</p><p class="depth0"><em>(1)</em> Original  application. An applicant shall submit with its original application  submitted under this part, including an application described in section  505(b)(2) of the act, the information described in paragraph (c) of this  section on each drug (ingredient), drug product (formulation and  composition), and method of use patent issued before the application is  filed with FDA and for which patent information is required to be  submitted under this section. If a patent is issued after the  application is filed with FDA but before the application is approved,  the applicant shall, within 30 days of the date of issuance of the  patent, submit the required patent information in an amendment to the  application under Sec. 314.60.</p><p class="depth0"><em>(2)</em> Supplements. </p><p class="depth0"><em>(i)</em> An applicant shall submit patent information  required under paragraph (c) of this section for a patent that claims  the drug, drug product, or method of use for which approval is sought in  any of the following supplements:</p><p class="depth0"><em>(A)</em> To change the formulation;</p><p class="depth0"><em>(B)</em> To add a new indication or other condition of use, including a  change in route of administration;</p><p class="depth0"><em>(C)</em> To change the strength;</p><p class="depth0"><em>(D)</em> To make any other patented change regarding the drug, drug  product, or any method of use.</p><p class="depth0"><em>(ii)</em> If the applicant submits a supplement for one of the changes  listed under paragraph (d)(2)(i) of this section and existing patents  for which information has already been submitted to FDA claim the  changed product, the applicant shall submit a certification with the  supplement identifying the patents that claim the changed product.</p><p class="depth0"><em>(iii)</em> If the applicant submits a supplement for one of the changes  listed under paragraph (d)(2)(i) of this section and no patents,  including previously submitted patents, claim the changed product, it  shall so certify.</p><p class="depth0"><em>(iv)</em> The applicant shall comply with the requirements for amendment  of formulation or composition and method of use patent information under  paragraphs (c)(2)(ii) and (d)(3) of this section.</p><p class="depth0"><em>(3)</em> Patent information deadline. If a patent is issued for a drug,  drug product, or method of use after an application is approved, the  applicant shall submit to FDA the required patent information within 30  days of the date of issuance of the patent.</p><p class="depth0"><em>(4)</em> Copies. The applicant shall submit two copies of each submission  of patent information, an archival copy and a copy for the chemistry,  manufacturing, and controls section of the review copy, to the Central  Document Room, Center for Drug Evaluation and Research, Food and Drug  Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. The  applicant shall submit the patent information by letter separate from,  but at the same time as, submission of the supplement.</p><p class="depth0"><em>(5)</em> Submission date. Patent information shall be considered to be  submitted to FDA as of the date the information is received by the  Central Document Room.</p><p class="depth0"><em>(6)</em> Identification. Each submission of patent information, except  information submitted with an original application, and its mailing  cover shall bear prominent identification as to its contents, i.e.,  ``Patent Information,'' or, if submitted after approval of an  application, ``Time Sensitive Patent Information.''</p><p class="depth0"><em>(e)</em> Public disclosure of patent information. FDA will publish in the  list the patent number and expiration date of each patent that is  required to be, and is, submitted to FDA by an applicant, and for each  use patent, the approved indications or other conditions of use covered  by a patent. FDA will publish such patent information upon approval of  the application, or, if the patent information is submitted by the  applicant after approval of an application as provided under paragraph  (d)(2) of this section, as soon as possible after the submission to the  agency of the patent information. Patent information submitted by the  last working day of a month will be published in that month's supplement  to the list. Patent   information received by the Agency between monthly publication of  supplements to the list will be placed on public display in FDA's  Division of Freedom of Information. A request for copies of the file  shall be sent in writing to the Freedom of Information Staff at the  address listed on the Agency's Web site at http://www.fda.gov.</p><p class="depth0"><em>(f)</em> Correction of patent information errors. If any person disputes  the accuracy or relevance of patent information submitted to the agency  under this section and published by FDA in the list, or believes that an  applicant has failed to submit required patent information, that person  must first notify the agency in writing stating the grounds for  disagreement. Such notification should be directed to the Office of  Generic Drugs, OGD Document Room, Attention: Orange Book Staff, 7500  Standish Pl., Rockville, MD 20855. The agency will then request of the  applicable new drug application holder that the correctness of the  patent information or omission of patent information be confirmed.  Unless the application holder withdraws or amends its patent information  in response to FDA's request, the agency will not change the patent  information in the list. If the new drug application holder does not  change the patent information submitted to FDA, a 505(b)(2) application  or an abbreviated new drug application under section 505(j) of the act  submitted for a drug that is claimed by a patent for which information  has been submitted must, despite any disagreement as to the correctness  of the patent information, contain an appropriate certification for each  listed patent.  [59 FR 50363, Oct. 3, 1994, as amended at 68 FR 36703, June 18, 2003; 69  FR 13473, Mar. 23, 2004; 74 FR 9766, Mar. 6, 2009; 74 FR 36605, July 24,  2009; 76 FR 31470, June 1, 2011; 79 FR 68115, Nov. 14, 2014]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
